Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Retina > Teleretinal screening for diabetic retinopathy may improve screening rates
  • Retina

Teleretinal screening for diabetic retinopathy may improve screening rates

Ophthalmology 360
Teleretinal screening for diabetic retinopathy may improve screening rates

Utilizing teleretinal screenings for vitreoretinal conditions, including diabetic retinopathy (DR) may expand screening capacity and improve access to care in a cost-effective way, according to a presentation at Hawaiian Eye & Retina 2021.  

With teleretinal screening, a patient in need is identified, often by their primary care doctor. A trained professional then uses a telecompatible camera to collect images and upload them to a HIPAA compliant cloud-based server. An automated image interpretation is performed, and recommendations are delivered to the patients.

According to the presentation, teleretinal screenings have been proven to be effective in detecting DR. One study involving 935 patients who underwent both teleretinal screening and in-person evaluation, found that 86.2% of teleretinal screenings grades were within 1 DR severity level pf the grade determined at the clinical exam.

In addition, compliance has also been shown to improve with DR screening. One program saw compliance increase from 62% to 80% within the first year of use, while another found that implementing teleretinal screenings saved patients in rural areas approximately 1,900 hours of driving time over the course of 2 years by eliminating the need to drive to an urban center.

Despite its benefits, there are still some challenges that need to be overcome in order to make the most of teleretinal screening, including improving image quality, increase post-screening follow-up compliance, and advocating for financial sustainability.

The presentation was concluded by emphasizing that teleretina should be considered “adjunctive technology” and not a replacement of ophthalmologists.

Reference
Weng C. Challenges in teleretinal screening for diabetic retinopathy. Presented at: Hawaiian Eye & Retina 2021.

Share

Related Content

  • Retina

Biosimilar aflibercept-ayyh demonstrates favorable real-world safety and efficacy

  • Retina

Switching to aflibercept 8 mg improved anatomical outcomes in previously treated nAMD

Neovascular Age-related Macular Degeneration: Emerging Therapies With an EYE On Treatment Frequency
  • Retina

Treat-and-extend aflibercept 8 mg improves outcomes in nAMD over 1 year

  • Retina

Intravitreal therapy in nAMD linked to lower depression and anxiety risk

  • Retina

Alternative aflibercept regimens maintained efficacy in wet AMD

  • Retina

Nanoscope Therapeutics is working on the potential first-ever optogenetic therapy for retinal diseases

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon